semaglutide vs bariatric surgery Metabolic vs. GLP-1 Receptor Agonists for Obesity Management Medicine Guide – Tagged "GLP-1

References de Souto Barreto P, Rolland Y

Retatrutide (research grade), also designated LY3437943, is a long-acting synthetic peptide engineered to co-engage three distinct G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)

This efficacy in reducing body weight, combined with a favorable safety profile, led to the approval of Semaglutide for the treatment of obesity

Underscoring the potential health consequences from dosing errors and exposure to the wrong ingredients, in September 2025, the FDA reported receiving 1,150 reports of adverse events associated with compounded GLP-1 drugs, including hospitalizations and some deaths